Tīmeklis2024. gada 27. jūl. · LAM-002A is a first in class, highly selective PIKfyve kinase inhibitor 1,2 that has demonstrated potent in vitro antiviral activity against several … Tīmeklis2024. gada 28. jūl. · LAM-002A is a highly selective PIKfyve kinase inhibitor. In-vitro, the drug candidate showed potent antiviral activity against various isolates of SARS-CoV …
AI Therapeutics Announces Initiation of a Phase II Clinical
Tīmeklis*LAM-002A is the current formulation being studied in the AIT-101 program To learn more, click here to visit ClinicalTrials.gov. (ClinicalTrials.gov Identifier: NCT05163886) Expanded Access AI Therapeutics is committed to developing promising new therapies to address the unmet medical needs of patients suffering from rare orphan conditions. http://www.jinpanmed.cn/archives/date/2024/04/15 robert cromwell born 1390
LAM-002A – New Developments in Lymphoma
Tīmeklis2024. gada 27. jūl. · LAM-002A is a first in class, highly selective PIKfyve kinase inhibitor 1,2 that has demonstrated potent in vitro antiviral activity against several isolates of SARS-CoV-2, the virus responsible... Tīmeklis2024. gada 6. apr. · The Phase 2a clinical trial was conducted with the current formulation of AIT-101, also known as LAM-002A. Additional information is available at www.clinicaltrials.gov (NCT05163886). About AIT-101 . AIT-101 is a first-in-class, potent and highly selective inhibitor of the lipid kinase PIKfyve. Inhibition of PIKfyve leads to … Tīmeklis2024. gada 30. janv. · LAM-002 (apilimod) is an inhibitor of the PIKfyve kinase that works by clearing toxic protein aggregates, or clumps, within lysosomes — cell compartments in which unwanted molecules are broken down or digested. Abnormal lysosomal function is commonly observed in neurodegenerative diseases like … robert crook cortlandt manor ny obit